Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALIM Alimera Sciences	$5.54	$5.55	$2.61 ▼ $5.65	$290.24M	1.25	376,318 shs	N/A
AVDL Avadel Pharmaceuticals	$11.08 +5.4%	$9.78	$6.38 ▼ $17.30	$1.07B	1.47	986,045 shs	993,392 shs
PAHC Phibro Animal Health	$26.11 -1.5%	$26.70	$16.16 ▼ $31.80	$1.07B	0.8	303,453 shs	356,504 shs
PRAX Praxis Precision Medicines	$54.09 -0.2%	$47.05	$26.70 ▼ $91.83	$1.10B	2.62	443,884 shs	637,762 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALIM Alimera Sciences	0.00%	0.00%	0.00%	0.00%	-0.36%
AVDL Avadel Pharmaceuticals	+5.42%	+0.45%	+25.77%	+27.50%	-32.19%
PAHC Phibro Animal Health	-1.47%	-10.52%	-6.55%	+34.03%	+38.29%
PRAX Praxis Precision Medicines	-0.24%	-8.66%	+16.77%	+34.42%	-6.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	2.6715 of 5 stars	3.5	2.0	0.0	0.0	3.4	1.7	0.6
PAHC Phibro Animal Health	4.1332 of 5 stars	0.9	5.0	2.5	1.1	3.4	3.3	2.5
PRAX Praxis Precision Medicines	2.4185 of 5 stars	4.4	1.0	0.0	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALIM Alimera Sciences	0.00	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.33	65.46% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-6.55% Downside
PRAX Praxis Precision Medicines	2.78	Moderate Buy	$94.11	73.99% Upside

Current Analyst Ratings Breakdown

Latest ALIM, PRAX, PAHC, and AVDL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$22.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALIM Alimera Sciences	$99.68M	2.91	N/A	N/A	$0.88 per share	6.30
AVDL Avadel Pharmaceuticals	$194.45M	5.51	N/A	N/A	$0.77 per share	14.39
PAHC Phibro Animal Health	$1.02B	1.04	$2.08 per share	12.54	$6.34 per share	4.12
PRAX Praxis Precision Medicines	$8.55M	128.87	N/A	N/A	$23.90 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALIM Alimera Sciences	-$20.13M	-$1.57	N/A	26.38	N/A	-14.74%	-33.70%	-9.63%	N/A
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	184.67	N/A	-13.58%	-36.07%	-16.30%	8/7/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	33.47	12.43	0.44	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)

Latest ALIM, PRAX, PAHC, and AVDL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	N/A	N/A	N/A	$362.24 million	N/A
8/12/2025	Q2 2025	PRAX Praxis Precision Medicines	-$3.40	N/A	N/A	N/A	$0.16 million	N/A
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	N/A	N/A	N/A	$60.28 million	N/A
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALIM Alimera Sciences	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.84%	N/A	61.54%	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Latest ALIM, PRAX, PAHC, and AVDL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALIM Alimera Sciences	1.80	2.79	2.62
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
PAHC Phibro Animal Health	2.67	2.91	1.23
PRAX Praxis Precision Medicines	N/A	8.44	8.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALIM Alimera Sciences	99.83%
AVDL Avadel Pharmaceuticals	69.19%
PAHC Phibro Animal Health	99.34%
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
ALIM Alimera Sciences	31.40%
AVDL Avadel Pharmaceuticals	5.20%
PAHC Phibro Animal Health	50.07%
PRAX Praxis Precision Medicines	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALIM Alimera Sciences	150	52.39 million	35.94 million	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable

ALIM, PRAX, PAHC, and AVDL Headlines

Recent News About These Companies

Y Intercept Hong Kong Ltd Makes New $237,000 Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX)

July 31 at 4:41 AM | marketbeat.com

Chardan Capital Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX)

July 30 at 8:26 AM | marketbeat.com

Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT ...

July 30 at 4:31 AM | bakersfield.comB

Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results

July 30 at 4:31 AM | finance.yahoo.com

Praxis Precision Medicines (NASDAQ:PRAX) Given "Buy" Rating at Chardan Capital

July 30 at 3:03 AM | americanbankingnews.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $94.11 Consensus PT from Brokerages

July 26, 2025 | americanbankingnews.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Moderate Buy" from Analysts

July 23, 2025 | marketbeat.com

Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A ...

July 19, 2025 | finanznachrichten.de

Praxis Precision Gets FDA's Breakthrough Designation for Seizure Treatment

July 18, 2025 | marketwatch.com

Praxis Precision Medicines (NASDAQ:PRAX) Earns Buy Rating from HC Wainwright

July 18, 2025 | marketbeat.com

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for ...

July 17, 2025 | bakersfield.comB

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

July 17, 2025 | globenewswire.com

Brokers Offer Predictions for PRAX Q1 Earnings

July 16, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 10.4% on Analyst Upgrade

July 9, 2025 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $115.00 at Oppenheimer

July 8, 2025 | marketbeat.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule ...

July 2, 2025 | gurufocus.com

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 2, 2025 | globenewswire.com

Former head trader of Denver-based investing company pleads guilty to insider trading

June 9, 2025 | finance.yahoo.com

Weston man pleads guilty to insider trading offense that made him $220K

June 8, 2025 | stamfordadvocate.comS

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 4, 2025 | globenewswire.com

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

May 7, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM, PRAX, PAHC, and AVDL Company Descriptions

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Avadel Pharmaceuticals NASDAQ:AVDL

$11.08 +0.57 (+5.42%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$11.02 -0.05 (-0.50%)

As of 08/1/2025 07:15 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Phibro Animal Health NASDAQ:PAHC

$26.11 -0.39 (-1.47%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$26.12 +0.02 (+0.06%)

As of 08/1/2025 04:32 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Praxis Precision Medicines NASDAQ:PRAX

$54.09 -0.13 (-0.24%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$51.76 -2.33 (-4.31%)

As of 08/1/2025 07:49 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time